US 12,331,107 B2
Methods of treating pneumonia or respiratory failure associated with COVID-19 by administering an anti-LIGHT antibody
Garry A. Neil, Havertown, PA (US); and Inbal Zafir-Lavie, Misgav (IL)
Assigned to Avalo Therapeutics, Inc., Rockville, MD (US)
Filed by Avalo Therapeutics, Inc., Rockville, MD (US)
Filed on Jun. 5, 2023, as Appl. No. 18/329,069.
Application 18/329,069 is a continuation of application No. 17/218,449, filed on Mar. 31, 2021, granted, now 11,708,406.
Claims priority of provisional application 63/133,636, filed on Jan. 4, 2021.
Claims priority of provisional application 63/027,127, filed on May 19, 2020.
Claims priority of provisional application 63/003,826, filed on Apr. 1, 2020.
Prior Publication US 2024/0002492 A1, Jan. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/24 (2006.01); A61K 31/706 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 1/00 (2006.01); A61P 29/00 (2006.01); A61P 31/14 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/241 (2013.01) [A61K 31/706 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 1/00 (2018.01); A61P 29/00 (2018.01); A61P 31/14 (2018.01); G01N 33/6863 (2013.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01); C07K 2317/90 (2013.01); G01N 2333/525 (2013.01)] 8 Claims
 
1. A method of treating pneumonia associated with COVID-19 comprising administering to a human subject in need thereof an effective amount of an anti-LIGHT antibody comprising a heavy chain and a light chain variable region comprising a CDR-H1 having the sequence of SEQ ID NO: 2, CDR-H2 having the sequence of SEQ ID NO: 3, CDR-H3 having the sequence of SEQ ID NO: 4, CDR-L1 having the sequence of SEQ ID NO: 5, CDR-L2 having the sequence of SEQ ID NO: 6, and CDR-L3 having the sequence of SEQ ID NO: 7.